Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.
作者： G Peiró , F Ortiz-Martínez , A Gallardo , A Pérez-Balaguer , J Sánchez-Payá
DOI: 10.1038/BJC.2014.327
关键词:
摘要: Src is a non-receptor tyrosine kinase involved in signalling and crosstalk between growth-promoting pathways. We aim to investigate the relationship of active response trastuzumab HER2-positive breast carcinomas. selected 278 cancer patients with (n=154) without (n=124) treatment. performed immunohistochemistry on paraffin-embedded tissue microarrays several proteins PI3K/Akt/mTOR pathway, PIK3CA mutational analysis vitro studies (SKBR3 BT474 cells). The results were correlated clinicopathological factors patients’ outcome. Increased pSrc-Y416 was demonstrated trastuzumab-resistant cells 37.8% tumours that positively tumour size, necrosis, mitosis, metastasis central nervous system, p53 overexpression MAPK activation but inversely EGFR p27. Univariate analyses showed an association increased shorter survival at early stage HER2/hormone receptor-negative treated trastuzumab. participates mechanisms resistance indicates poor prognosis, mainly cancer. Therefore, blocking this axis may be beneficial those patients.
nature.com
sci-hub.se 参考文章(38)
Francisco J. Esteva, Hua Guo, Siyuan Zhang, Cesar Santa-Maria, Steven Stone, Jerry S. Lanchbury, Aysegul A. Sahin, Gabriel N. Hortobagyi, Dihua Yu, PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. American Journal of Pathology. ,vol. 177, pp. 1647- 1656 ,(2010) , 10.2353/AJPATH.2010.090885
Klaus Jürgen Schmitz, Florian Grabellus, Rainer Callies, Friedrich Otterbach, Jeremias Wohlschlaeger, Bodo Levkau, Rainer Kimmig, Kurt Werner Schmid, Hideo Andreas Baba, High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome Breast Cancer Research. ,vol. 7, pp. 1- 10 ,(2005) , 10.1186/BCR977
M Cizkova, M-E Dujaric, J Lehmann-Che, V Scott, O Tembo, B Asselain, J-Y Pierga, M Marty, P de Cremoux, F Spyratos, I Bieche, Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab British Journal of Cancer. ,vol. 108, pp. 1807- 1809 ,(2013) , 10.1038/BJC.2013.164
Rita Nahta, Takeshi Takahashi, Naoto T. Ueno, Mien-Chie Hung, Francisco J. Esteva, P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells Cancer Research. ,vol. 64, pp. 3981- 3986 ,(2004) , 10.1158/0008-5472.CAN-03-3900
Dominique Stehelin, Donald J. Fujita, Thomas Padgett, Harold E. Varmus, J.Michael Bishop, Detection and enumeration of transformation-defective strains of avian sarcoma virus with molecular hybridization Virology. ,vol. 76, pp. 675- 684 ,(1977) , 10.1016/0042-6822(77)90250-1
Satyajit K Mitra, David D Schlaepfer, Integrin-regulated FAK-Src signaling in normal and cancer cells. Current Opinion in Cell Biology. ,vol. 18, pp. 516- 523 ,(2006) , 10.1016/J.CEB.2006.08.011
Shizhen Emily Wang, Bin Xiang, Roy Zent, Vito Quaranta, Ambra Pozzi, Carlos L. Arteaga, Transforming Growth Factor β Induces Clustering of HER2 and Integrins by Activating Src-Focal Adhesion Kinase and Receptor Association to the Cytoskeleton Cancer Research. ,vol. 69, pp. 475- 482 ,(2009) , 10.1158/0008-5472.CAN-08-2649
Robert Roskoski, Src kinase regulation by phosphorylation and dephosphorylation Biochemical and Biophysical Research Communications. ,vol. 331, pp. 1- 14 ,(2005) , 10.1016/J.BBRC.2005.03.012
R C Ishizawar, T Miyake, S J Parsons, c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function Oncogene. ,vol. 26, pp. 3503- 3510 ,(2007) , 10.1038/SJ.ONC.1210138
Brent N Rexer, A-JL Ham, Cammie Rinehart, Salisha Hill, Nara de Matos Granja-Ingram, AM Gonzalez-Angulo, Gordon B Mills, Bhuvanesh Dave, Jenny C Chang, Daniel C Liebler, Carlos L Arteaga, None, Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition Oncogene. ,vol. 30, pp. 4163- 4174 ,(2011) , 10.1038/ONC.2011.130